{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:07:05Z","timestamp":1783577225929,"version":"3.55.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p><jats:bold>Introduction<jats:italic>:<\/jats:italic><\/jats:bold> The selective Bcl-2 inhibitor venetoclax has shown promising therapeutic potential in multiple myeloma, particularly in cases associated with t(11;14) <jats:italic>IGH::CCND1<\/jats:italic> translocation. However, the efficacy of venetoclax in myeloma patients with the t(6;14) <jats:italic>IGH::CCND3<\/jats:italic> translocation remains less investigated.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed\/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed. Clinical data, laboratory results, and adverse events were analyzed to evaluate treatment outcomes.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Our findings demonstrated remarkable therapeutic responses in three consecutive patients with t(6;14) translocation-associated myeloma who received venetoclax-based therapy. Patient 1, a lenalidomide-bortezomib-daratumumab and alkylator treatment refractory patient, achieved sustained stringent complete remission (sCR) after combining carfilzomib-dexamethasone with venetoclax, which was his best response ever. Similarly, Patient 2, refractory to frontline bortezomib-thalidomide-dexamethasone therapy, attained CR following a transition to bortezomib-dexamethason-venetoclax treatment. Patient 3, who was immunomodulatory (IMID)-intolerant, showed a highly favorable response to venetoclax-dexamethasone therapy after his first relapse following autologous stem cell transplantation. No significant adverse effects were observed in any of the patients.<\/jats:p><jats:p><jats:bold>Discussion:<\/jats:bold> Our study provides compelling preliminary evidence for the efficacy of venetoclax in t(6;14) translocation-associated myeloma. The outcomes observed in our patients suggest that venetoclax-based therapy holds substantial promise as an effective treatment option for this specific genetic subgroup. Furthermore, the similarities in treatment response between t(11;14) and t(6;14) translocation subgroups highlight the importance of personalized approaches targeting specific genetic abnormalities to optimize therapeutic outcomes.<\/jats:p>","DOI":"10.3389\/pore.2023.1611375","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T10:41:38Z","timestamp":1699612898000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Effective venetoclax-based treatment in relapsed\/refractory multiple myeloma patients with translocation t(6;14)"],"prefix":"10.3389","volume":"29","author":[{"given":"Andrea","family":"Cegl\u00e9di","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Csukly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nika","family":"Fekete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Kozma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Szemlaky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajnalka","family":"Andrikovics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Mikala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s11357-022-00698-x","article-title":"Multiple myeloma, a quintessential malignant disease of aging: a geroscience perspective on pathogenesis and treatment","volume":"45","author":"Urban","year":"2023","journal-title":"Geroscience"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1200\/JCO.21.00443","article-title":"Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14)","volume":"39","author":"Bahlis","year":"2021","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ajh.26083","article-title":"Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma","volume":"96","author":"Kaufman","year":"2021","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1007\/s00277-021-04555-3","article-title":"Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed\/refractory multiple myeloma patients-a single-center retrospective study","volume":"100","author":"Regidor","year":"2021","journal-title":"Ann Hematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41698-022-00315-2","article-title":"Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)","volume":"6","author":"Nguyen","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13256-020-02376-y","article-title":"Venetoclax in combination with carfilzomib and dexamethasone in relapsed\/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature","volume":"14","author":"Abuelgasim","year":"2020","journal-title":"J Med Case Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/bjh.16454","article-title":"Real-world data on safety and efficacy of venetoclax-based regimens in relapsed\/refractory t(11;14) multiple myeloma","volume":"189","author":"Basali","year":"2020","journal-title":"Br J Haematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1111\/bjh.16483","article-title":"Carfilzomib, venetoclax and dexamethasone for relapsed\/refractory multiple myeloma","volume":"189","author":"Boccon-Gibod","year":"2020","journal-title":"Br J Haematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1182\/bloodadvances.2020004146","article-title":"Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"5","author":"Costa","year":"2021","journal-title":"Blood Adv"},{"key":"B11","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.clml.2021.07.029","article-title":"A phase II study of venetoclax in combination with pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma","volume":"21","author":"Gasparetto","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/07853890.2023.2186480","article-title":"Efficacy and safety of Venetoclax-based regimens in relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials","volume":"55","author":"He","year":"2023","journal-title":"Ann Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.3324\/haematol.2019.232330","article-title":"Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient","volume":"105","author":"Kovacs","year":"2020","journal-title":"Haematologica"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/ajh.26269","article-title":"Venetoclax for the treatment of multiple myeloma: outcomes outside of clinical trials","volume":"96","author":"Sidiqi","year":"2021","journal-title":"Am J Hematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.3324\/haematol.2019.228338","article-title":"Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14)","volume":"105","author":"Swan","year":"2020","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1610276","DOI":"10.3389\/pore.2022.1610276","article-title":"Targeted venetoclax therapy in t(11;14) multiple myeloma: real world data from seven hungarian centers","volume":"28","author":"Szita","year":"2022","journal-title":"Pathol Oncol Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.3324\/haematol.2016.160408","article-title":"Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14)","volume":"102","author":"Touzeau","year":"2017","journal-title":"Haematologica"},{"key":"B19","doi-asserted-by":"publisher","first-page":"6285","DOI":"10.3390\/cancers13246285","article-title":"Infections of venetoclax-based chemotherapy in acute myeloid leukemia: rationale for proper antimicrobial prophylaxis","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/ejh.13753","article-title":"Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents","volume":"108","author":"Papayannidis","year":"2022","journal-title":"Eur J Haematol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7031","DOI":"10.1007\/s00520-022-07126-y","article-title":"A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia","volume":"30","author":"Zhu","year":"2022","journal-title":"Support Care Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"eabg9551","DOI":"10.1126\/sciadv.abg9551","article-title":"Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications","volume":"7","author":"Bhalla","year":"2021","journal-title":"Sci Adv"},{"key":"B23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.bbmt.2005.10.002","article-title":"Using genomics to identify high-risk myeloma after autologous stem cell transplantation","volume":"12","author":"Shaughnessy","year":"2006","journal-title":"Biol Blood Marrow Transpl"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1038\/s41375-020-0785-1","article-title":"Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis","volume":"34","author":"Sarin","year":"2020","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.1158\/1078-0432.CCR-16-0867","article-title":"Gene expression profiles in myeloma: ready for the real world?","volume":"22","author":"Szalat","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1182\/blood.2020007899","article-title":"Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression","volume":"137","author":"Gupta","year":"2021","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.3390\/cancers13194898","article-title":"Transcriptomic analysis in multiple myeloma and primary plasma cell leukemia with t(11;14) reveals different expression patterns with biological implications in venetoclax sensitivity","volume":"13","author":"Todoerti","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/s41467-020-15051-z","article-title":"Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma","volume":"11","author":"Bajpai","year":"2020","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/s41375-018-0374-8","article-title":"Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma","volume":"33","author":"Matulis","year":"2019","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1755-8794-7-25","article-title":"Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use","volume":"7","author":"van Laar","year":"2014","journal-title":"BMC Med Genomics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1182\/blood-2007-10-119321","article-title":"High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone","volume":"111","author":"Zhan","year":"2008","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.beha.2005.02.003","article-title":"Gene expression profiling and multiple myeloma","volume":"18","author":"Shaughnessy","year":"2005","journal-title":"Best Pract Res Clin Haematol"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2023.1611375\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T10:41:41Z","timestamp":1699612901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2023.1611375\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":33,"alternative-id":["10.3389\/pore.2023.1611375"],"URL":"https:\/\/doi.org\/10.3389\/pore.2023.1611375","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]},"article-number":"1611375"}}